• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Identification of a potent regulatory T cell epitope infactor V that modulates CD4+ and CD8+ memory T cell responses

Identification of a potent regulatory T cell epitope infactor V that modulates CD4+ and CD8+ memory T cell responses

by Annie De Groot | Jan 13, 2021

FV621 De Groot et al 2021
Immune camouflage: Relevance to vaccines and human immunology

Immune camouflage: Relevance to vaccines and human immunology

by Annie De Groot | Jan 13, 2020

De Groot et al. – 2014 – Immune camouflage Relevance to vaccines and human immunology
Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction

Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction

by Annie De Groot | Nov 12, 2019

Tregitope in T1D Nature Scientific Reports With Suppliment Nov 2019
New Regression Model Predicts Antibody Immunogenicity Based on Effector and Regulatory T Cell Epitope Content

New Regression Model Predicts Antibody Immunogenicity Based on Effector and Regulatory T Cell Epitope Content

by Annie De Groot | Dec 14, 2018

EpiVax_AET18_New Regression Model Predicts Antibody Immunogenicity_5Dec18
Effector and Regulatory T Cell Epitope Content, and not Humanization nor Biophysical Properties, is Predictive of Antibody Immunogenicity

Effector and Regulatory T Cell Epitope Content, and not Humanization nor Biophysical Properties, is Predictive of Antibody Immunogenicity

by Annie De Groot | Oct 9, 2018

EpiVax_Effector_and_Regulatory_T_Cell_Epitope_Content_is_Predictive_of_Antibody_Immunogenicity_05Oct18
« Older Entries
Next Entries »

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline